文献速递物质与行为成瘾

酒精使用障碍概览

Overview of Alcohol Use Disorder.
PubMed 文献 · Am J Psychiatry · 2023-01-01

酒精使用障碍(AUD)在美国12岁及以上人群中患病率为11%,终生诊断者接受治疗的比例不足15%。AUD风险遗传与环境因素几乎同等重要,对心理社会治疗和药物治疗均有反应。美国批准的双硫仑、纳曲酮和乙酰半胱氨酸虽为指南一线治疗但处方不足,托吡酯和加巴喷丁超说明书使用有效,新型药物候选物如致幻剂和磷酸二酯酶-4抑制剂需进一步评估。

要点

  • AUD美国患病率11%,终生诊断者治疗率不足15%。
  • 美国批准的双硫仑、纳曲酮和乙酰半胱氨酸为指南一线但处方不足。
  • 托吡酯和加巴喷丁超说明书使用对AUD有效。

核心结论

  • AUD是常见且可治疗但治疗不足的疾病,心理社会与药物治疗有效,需减少污名并改善识别与治疗。

研究设计与样本

  • 本文为综述,未报告系统检索范围与样本量。

主要发现

  • AUD美国患病率为11%,终生诊断者接受任何治疗的比例不足15%。
  • AUD风险遗传与环境因素几乎同等重要。
  • 重饮酒每年在美国导致超过140,000人死亡。

关键数值与推荐

  • 美国批准治疗AUD的药物为双硫仑、纳曲酮(口服和长效注射剂型)和乙酰半胱氨酸,指南视为一线治疗。
  • 托吡酯和加巴喷丁未批准用于AUD但显示有效,超说明书使用。
  • 致幻剂和磷酸二酯酶-4抑制剂等新型候选药物需进一步评估后才能临床使用。

临床怎么用

  • AUD应使用心理社会治疗如认知行为疗法和动机增强疗法。
  • 指南一线药物双硫仑、纳曲酮和乙酰半胱氨酸应更广泛处方。
  • 托吡酯和加巴喷丁可超说明书用于AUD治疗。

局限性

  • 本文为综述,未报告系统检索策略、纳入标准及证据质量评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alcohol is regularly consumed throughout most of the world, including by nearly half the U.S. population age 12 or older. Heavy drinking, which is also common, contributes to multiple adverse medical, psychiatric, and social outcomes and more than 140,000 deaths annually in the United States. It is the major risk factor for alcohol use disorder (AUD), whose current U.S. prevalence is 11%. However, AUD is undertreated, with less than 15% of individuals with a lifetime diagnosis receiving any treatment. Risk of AUD is nearly equally genetic and environmental. AUD is responsive to psychosocial treatments, including cognitive-behavioral therapy and motivational enhancement therapy. Alcohol affects multiple neurotransmitter systems, and thus pharmacotherapy for AUD is also effective. The three medications approved in the United States to treat AUD-disulfiram, naltrexone (oral and long-acting injectable formulations), and acamprosate-are underprescribed, despite being considered first-line treatments in clinical practice guidelines. Two medications not approved for treating AUD, topiramate and gabapentin, have shown efficacy in treating the disorder and are used off-label. Recent studies of novel drug candidates, including psychedelics and phosphodiesterase-4 inhibitors, are promising additions for the treatment of AUD, although they require further evaluation before being used clinically. Despite the growing availability of efficacious psychosocial and pharmacological treatments for AUD, it remains a highly stigmatized condition. Research aimed at enhancing the identification and treatment of AUD, including precision therapeutics, could broaden the acceptability of AUD treatment, benefiting affected individuals and their families and reducing the stigma associated with the disorder.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kranzler HR. Overview of Alcohol Use Disorder. Am J Psychiatry. 2023. PMID: 37525595. doi:10.1176/appi.ajp.20230488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。